Biolife solutions reports fourth quarter and full year 2024 financial results

Cell processing revenue up 7%  sequentially to $20.3 million in the fourth quarter; 2024 cell processing revenue up 12%  over prior year to $73.5 million gaap gross margin of 60%  and non-gaap adjusted gross margin of 63%  for the fourth quarter gaap net loss from continuing operations of $2.0 million and non-gaap adjusted ebitda of $4.0 million, or 18%  of total revenue for the fourth quarter expects 2025  cell processing revenue of $86.5 to $89.0 million, up 18%  to 21%  over 2024 and total revenue of $95.5 to $99.0 million, up 16%  to 20%  over 2024 conference call begins at 8:00 a.m. eastern time today  bothell, wash.
BLFS Ratings Summary
BLFS Quant Ranking